TWI433672B - 吲唑化合物 - Google Patents

吲唑化合物 Download PDF

Info

Publication number
TWI433672B
TWI433672B TW096146086A TW96146086A TWI433672B TW I433672 B TWI433672 B TW I433672B TW 096146086 A TW096146086 A TW 096146086A TW 96146086 A TW96146086 A TW 96146086A TW I433672 B TWI433672 B TW I433672B
Authority
TW
Taiwan
Prior art keywords
compound
nmr
cdcl
mhz
group
Prior art date
Application number
TW096146086A
Other languages
English (en)
Chinese (zh)
Other versions
TW200836720A (en
Inventor
Chung Ming Sun
Min Liang Kuo
Original Assignee
Univ Nat Taiwan
Univ Nat Chiao Tung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Nat Taiwan, Univ Nat Chiao Tung filed Critical Univ Nat Taiwan
Publication of TW200836720A publication Critical patent/TW200836720A/zh
Application granted granted Critical
Publication of TWI433672B publication Critical patent/TWI433672B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/48—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with two nitrogen atoms as the only ring hetero atoms
    • A01N43/56—1,2-Diazoles; Hydrogenated 1,2-diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW096146086A 2006-12-05 2007-12-04 吲唑化合物 TWI433672B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87304106P 2006-12-05 2006-12-05
US11/949,070 US7825261B2 (en) 2006-12-05 2007-12-03 Indazole compounds

Publications (2)

Publication Number Publication Date
TW200836720A TW200836720A (en) 2008-09-16
TWI433672B true TWI433672B (zh) 2014-04-11

Family

ID=39492604

Family Applications (1)

Application Number Title Priority Date Filing Date
TW096146086A TWI433672B (zh) 2006-12-05 2007-12-04 吲唑化合物

Country Status (9)

Country Link
US (1) US7825261B2 (US06780888-20040824-C00057.png)
EP (1) EP2091329A4 (US06780888-20040824-C00057.png)
JP (1) JP2010511721A (US06780888-20040824-C00057.png)
KR (1) KR20090127867A (US06780888-20040824-C00057.png)
CN (1) CN101616587A (US06780888-20040824-C00057.png)
AU (1) AU2007329480A1 (US06780888-20040824-C00057.png)
CA (1) CA2671543A1 (US06780888-20040824-C00057.png)
TW (1) TWI433672B (US06780888-20040824-C00057.png)
WO (1) WO2008070599A1 (US06780888-20040824-C00057.png)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010059658A1 (en) * 2008-11-20 2010-05-27 Glaxosmithkline Llc Chemical compounds
DE102009049662A1 (de) 2009-10-13 2011-04-14 Bayer Schering Pharma Aktiengesellschaft 2,5-Disubstituierte 2H-Indazole als EP2-Rezeptor-Antagonisten
TWI450894B (zh) 2009-12-18 2014-09-01 Mitsubishi Tanabe Pharma Corp 新穎抗血小板藥
AU2011218830B2 (en) 2010-02-25 2014-07-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
TW201326154A (zh) 2011-11-28 2013-07-01 拜耳知識產權公司 作為ｅｐ２受體拮抗劑之新穎２ｈ－吲唑
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
JP6064062B2 (ja) 2013-03-15 2017-01-18 ファイザー・インク Ａｍｐｋを活性化させるインダゾール化合物
BR112015029214A2 (pt) 2013-05-23 2017-07-25 Bayer Pharma AG composição farmacêutica, seu uso e regime de aplicação dessa composição farmacêutica para contracepção conforme a necessidade
CA2917490A1 (en) 2013-07-09 2015-01-15 Takeda Pharmaceutical Company Limited Heterocyclic compound
KR101713303B1 (ko) 2015-12-24 2017-03-07 강원대학교산학협력단 2ｈ-인다졸 유도체의 제조방법
GB201617630D0 (en) 2016-10-18 2016-11-30 Cellcentric Ltd Pharmaceutical compounds
WO2019168847A1 (en) 2018-02-27 2019-09-06 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors
GB201806320D0 (en) 2018-04-18 2018-05-30 Cellcentric Ltd Process
EP3810610A1 (en) 2018-05-18 2021-04-28 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
KR20210049090A (ko) 2018-07-05 2021-05-04 인사이트 코포레이션 A2a/a2b 억제제로서 융합된 피라진 유도체
FI3860998T3 (fi) 2018-10-05 2024-03-27 Annapurna Bio Inc Yhdisteitä ja koostumuksia apj-reseptorin aktiivisuuteen liittyvien tautitilojen hoitoon
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
EP4146639A1 (en) 2020-05-06 2023-03-15 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
TW202241889A (zh) 2020-12-23 2022-11-01 美商雅捷可斯治療公司 作為ｊａｋ２抑制劑之６－雜芳基氧基苯并咪唑及氮雜苯并咪唑
WO2023086319A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. 6-he tero aryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2264798A1 (en) * 1996-09-04 1998-03-12 Pfizer Inc. Indazole derivatives and their use as inhibitors of phosphodiesterase (pde) type iv and the production of tumor necrosis factor (tnf)
AU779073B2 (en) * 1998-12-23 2005-01-06 Nps Allelix Corp. Indole and indolizidine derivatives for the treatment of migraine
US7141581B2 (en) * 1999-07-02 2006-11-28 Agouron Pharmaceuticals, Inc. Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
WO2003020698A2 (en) * 2001-09-06 2003-03-13 Prochon Biotech Ltd. Protein tyrosine kinase inhibitors
AU2003293376A1 (en) * 2002-12-10 2004-06-30 Imclone Systems Incorporated Anti-angiogenic compounds and their use in cancer treatment
CA2521907A1 (en) * 2003-04-10 2004-10-21 Pfizer Inc. Bicyclic compounds as nr2b receptor antagonists
KR20060005375A (ko) * 2003-04-18 2006-01-17 메모리 파마슈티칼스 코포레이션 포스포디에스테라제 4 억제제로서의 피라졸 유도체
WO2005105094A2 (en) * 2004-04-16 2005-11-10 Smithkline Beecham Corporation Cancer treatment method
JP2008516964A (ja) * 2004-10-15 2008-05-22 メモリー ファーマシューティカルス コーポレーション ホスホジエステラーゼ４阻害剤としてのピラゾール誘導体
ATE519488T1 (de) * 2004-12-27 2011-08-15 Novartis Ag Aminopyrazin-analoga zur behandlung von glaukomen und anderen durch rho-kinase verursachten krankheiten
JP5116687B2 (ja) * 2005-11-02 2013-01-09 バイエル・ファルマ・アクチェンゲゼルシャフト がんおよび他の過剰増殖性疾患の処置のためのピロロ［２，１−ｆ］［１，２，４］トリアジン−４−イルアミンＩＧＦ−１Ｒキナーゼ阻害剤

Also Published As

Publication number Publication date
EP2091329A4 (en) 2011-02-23
WO2008070599A1 (en) 2008-06-12
US20080132501A1 (en) 2008-06-05
CN101616587A (zh) 2009-12-30
CA2671543A1 (en) 2008-06-12
JP2010511721A (ja) 2010-04-15
AU2007329480A1 (en) 2008-06-12
EP2091329A1 (en) 2009-08-26
US7825261B2 (en) 2010-11-02
KR20090127867A (ko) 2009-12-14
TW200836720A (en) 2008-09-16

Similar Documents

Publication Publication Date Title
TWI433672B (zh) 吲唑化合物
CA2901022C (en) Substituted pyridine compounds as inhibitors of histone demethylases
AU721247B2 (en) Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses
US5919795A (en) Biphenyl-2-carboxylic acid-tetrahydro-isoquinolin-6-yl amide derivatives, their preparation and their use as inhibitors of microsomal triglyceride transfer protein and/or apolipoprotein B (Apo B) secretion
US5994294A (en) Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
JP3218037B2 (ja) 喘息および呼吸器官の炎症の治療に有用なヘテロサイクリックアミン類
EP2121612B1 (en) Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals
WO2006001463A1 (ja) Ｓ１ｐ受容体結合能を有する化合物およびその用途
TW202003466A (zh) 人類整合素α４β７拮抗劑
KR20030059084A (ko) 카르복사미드 화합물 및 이것의 사람 11ｃｂｙ 수용체의길항제로서의 용도
EP0832069A1 (en) BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION
KR20080006614A (ko) 증식 질환의 치료에 유용한 ｈｓｐ90 억제제인2-아미노-퀴나졸린-5-온
CA2369103A1 (en) Nitrogen-containing heterocyclic compounds and benamide compounds and drugs containing the same
WO2014079232A1 (zh) 7-氧代吡啶并嘧啶类化合物及其药用组合物和应用
KR102426138B1 (ko) ＰＩ3Ｋ, ｍＴＯＲ 저해제로서 융합된 퀴놀린 화합물
EP3303325A1 (en) Cannabinoid receptor mediating compounds
EP2919779A1 (en) Cannabinoid receptor mediating compounds
BR112019012515A2 (pt) antagonistas de integrina
WO2002020462A1 (fr) Derives d'acide benzoique et medicaments possedant ces derniers comme principe actif
JP2000063363A (ja) 新規なトリアゾール誘導体
WO2010006496A1 (zh) 用作雌激素相关受体调节剂的化合物及其应用
CN102149678A (zh) 用于治疗癌症的新型邻氨基酰苯胺类
JP5149794B2 (ja) 飽和リンカー基を含有するヘテロアリール置換アミドおよび医薬としてのその使用
JPWO2003101983A1 (ja) テトラヒドロピラン誘導体
CN111909133B (zh) 作为布鲁诺酪氨酸激酶抑制剂的取代的1-氨基-1h-咪唑-5-甲酰胺

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees